277results about How to "Avoid false negatives" patented technology

The invention discloses a novel coronavirus detection kit. The kit comprises a qRT-PCR reaction liquid, a qRT-PCR enzyme liquid, an internal standard, a negative quality control substance and a positive quality control substance, wherein the internal standard is an RNA pseudovirus containing an internal reference detection gene fragment; the positive quality control substance is an RNA pseudoviruscontaining a target detection gene fragment; and the qRT-PCR reaction liquid comprises four groups of upstream and downstream primers with sequences of SEQ ID NO:1-8 and four probes with sequences ofSEQ ID NO:9-12. The kit can be used to simultaneously detect three sections of target gene fragments, so that missed detection can be effectively avoided. In addition, pseudoviruses are used in boththe internal standard and the positive quality control substance of the kit, so that safety of the kit is effectively improved, and detection accuracy of the kit is further ensured. The kit is high sensitivity and good in stability.

The invention relates to a servo centering device of a rail flaw detection robot. The servo centering device of the rail flaw detection robot comprises at least one detection wheel and further comprises an integrated support, wherein the detection wheel is installed on the integrated support and is installed on a flaw detection trolley used for rail flaw detection operation, an adjusting system is formed on the integrated support, and when the flaw detection trolley conducts flaw detection operation, the adjusting system adjusts the operation state of the detection wheel in the horizontal direction, the vertical direction and the running direction of the detection wheel, so that the detection wheel and the top surface of a rail are always kept in good coupling to accurate receive, transmit flaw detection signals and avoid report mistakes and report failure.

The invention discloses a nucleic acid detection kit for human papilloma virus, a use method and an application thereof. The kit includes a nucleic acid amplification reagent comprising a primer pair and a probe corresponding to the primer pair. The use method of the kit includes the following steps: 1) extracting nucleic acids from a sample; 2) preparing the reagent; 3) performing PCR amplification; and 4) performing fluorescent detection to a PCR amplification reaction product at 65-72 DEG C, and determining infection type of the HPV according to the changes on the Ct value of a target amplification curve and the Ct value of an internal standard amplification curve. The kit can be used for detecting low-risk and high-risk human papilloma virus and for typing the human papilloma virus. The kit can be used for calculating relative viral load of the HPV, can avoid pollution, can increase treatment throughput of samples, and can avoid missing detection.

The invention relates to an intelligent monitoring method, device and system based on WiFi. The device comprises an intelligent WiFi AP (Access Point), which is used for detecting a WiFi signal intensity value in an early warning area, judging whether the WiFi signal intensity value is within a preset signal intensity range, judging whether the current early warning count exceeds an early warning count threshold after a set timing cycle, if so, sending and displaying prompt information, otherwise, not carrying out any processing. The method, the device and the system realize intelligent monitoring using the WiFi technology, thereby effectively avoiding user privacy divulgence and missing report defect; and intelligent monitoring can be realized by adding only one WiFi connector and sufficiently utilizing the existing household routing platform, so the method, the device and the system are low in cost, high in security and very suitable for large-area popularization.

The invention relates to the field of the biological technology and the medical examination technology, and provides a COVID-19 nucleic acid testing primer probe composition, a COVID-19 nucleic acid testing kit and a COVID-19 nucleic acid testing method for solving the problems of low accuracy, poor specificity and low sensitivity of a traditional virus nucleic acid testing method. The COVID-19 nucleic acid testing primer probe composition comprises a first primer probe group, a second primer probe group and a third primer probe group, wherein the first primer probe group comprises a forward primer ORF1ab-F, a probe ORF1ab-P and a reverse primer ORF1ab-R; the second primer probe group comprises a forward primer N-F, a probe N-P and a reverse primer N-R; and the third primer probe group comprises a forward primer Rpp30-F, a probe Rpp30-P and a reverse primer Rpp30-R. According to the primer probe composition disclosed by the invention, through artful design of an amplification primer pair and a detection probe, mutual interference between a plurality of primer pairs and corresponding detection probes is avoided. The kit has a simple structure, an interior label is used for monitoring a collection, transportation and extraction process of a sample to be detected, and the false negative of a detection result is avoided.

The invention discloses a DMD (Duchenne muscular dystrophy) gene capture probe and application thereof in DMD gene mutation detection. A preparation method of the DMD gene capture probe disclosed herein comprises: preparing N sub-probes, connecting the sub-probes to obtain the DMD gene capture probe; N is a natural number greater than or equal to 2; the N sub-probes can cover whole sequences of DMD gene; any two adjoining sub-probes on the DMD gene meet the case where there is one or more downstream nucleotide to the corresponding upstream sub-probe, which overlap with the upstream of the corresponding downstream sub-probe; the length of each of the N sub-probes is 50-150 bp. By detecting the DMD gene with the DMD gene capture probe, it is possible to detect whether the DMD gene experiences amplification mutation deletion/repetition or not, and it is also possible to precisely locate a break point region and the size of fragments and to detect DMD gene site mutations of a sample under detection.

The invention discloses an electrocardio normality/abnormality big-data processing method and device, and the method employs a normal electrocardio database, and comprises the following steps: S1, partitioning to-be-classified electrocardio data according to cardiac beat, and then carrying out the normalization processing of length and amplitude, thereby forming a plurality of pieces of beat-wave-shaped data; S2, extracting the index data of to-be-classified electrocardio data; S3, determining a confidence interval according to the index data stored in the database, comparing the index data of the extracted to-be-classified electrocardio data with the confidence interval, and outputting a comparison result; S4, calculating the similarity of the plurality of pieces of beat-wave-shaped data obtained through the partitioning of the to-be-classified electrocardio data with waveform data, corresponding to cardiac beat, in the electrocardio data stored in the database, comparing the similarity with a similarity threshold value, and outputting the comparison results. The device comprises the normal electrocardio database, and a plurality of modules which are used for achieving the above steps. The device can achieve the reliable classification and screening of the electrocardiogram which is not diagnosed, and avoids false negative.

The invention discloses a detection method for identifying the American classical PRRSV strain, the HP-PRRSV strain and a new-type viral NADC30 strain at the same time. In the method, a multiplex real-time fluorescence RT-PCR for identifying three kinds of strains at the same time is established based on an ABI7500 fluorescent quantitative PCR instrument, wherein the strains include the classical PRRSV strain, the highly-pathogenic HP-PRRSV strain with the deletion of L-amino acid at the 481st locus of the Nsp2 gene and the continuous deletion of 29 amino acids at the 533ird-561st loci of the Nsp2 gene, and NADC30like; specific primers and specific probes for the three kinds of strains are designed respectively based on the Nsp2 gene, universal primers and universal probes for PRRSV are designed according to the relatively conserved N gene, missing detection caused by Nsp2 region mutation can be effectively prevented, and false negative can be avoided.

The invention discloses a kit for synchronously detecting twenty-three meningitis pathogens and a detection method of the kit. The kit comprises DEPC (diethylpyrocarbonate) water, a 5*RT (reverse transcription) buffer, a reverse transcription primer, a reverse transcriptase, an X solution, a 10*PCR (polymerase chain reaction) buffer, a PCR primer, a 25mM magnesium chloride solution, a DNA (deoxyribonucleic acid) polymerase and a positive control, and is characterized in that the reverse transcription primer comprises RT amplification primers of the twelve meningitis pathogens and a human RNA (ribonucleic acid) internal reference, and has a gene sequence shown as SEQ ID NO. 1-13 (sequence identifier number 1-13), and the PCR primer comprises forward and reverse PCR amplification primers of the rest eleven meningitis pathogens, a human DNA internal reference and a reaction internal reference, and PCR amplification primers of the twelve meningitis pathogens and the human RNA internal reference, and has a gene sequence shown as SEQ ID NO. 14-52. The kit and the detection method have the advantages of high specificity, sensitivity, flux and reliability, low cost, and no false negative results.

The invention discloses a kit for synchronously detecting twenty-two respiratory tract pathogens and a detection method of the kit. The kit comprises DEPC (diethylpyrocarbonate) water, a 5*RT (reverse transcription) buffer, a reverse transcription primer, a reverse transcriptase, an X solution, a 10*PCR (polymerase chain reaction) buffer, a PCR primer, a 25mM magnesium chloride solution, a DNA (deoxyribonucleic acid) polymerase and a positive control, and is characterized in that the reverse transcription primer comprises RT amplification primers of the nine respiratory tract pathogens, and a reverse primer of a human RNA (ribonucleic acid) internal reference, and has a gene sequence shown as SEQ ID NO. 1-6 (sequence identifier number 1-6), and the PCR primer comprises forward and reverse PCR amplification primers of the rest thirteen respiratory tract pathogens, a forward and reverse amplification primer of a human DNA internal reference, a forward and reverse PCR amplification primer of a reaction internal reference, PCR amplification primers of the nine respiratory tract pathogens, and a PCR amplification primer of the human RNA internal reference, and has a gene sequence shown as SEQ ID NO. 7-44. The kit and the detection method have the advantages of high specificity, sensitivity, flux and reliability, low cost, and no false negative results.

The invention relates to the technical field of biological medicines, in particular to a kit for quantum dot nucleic acid detection of urinary tract infection-causing pathogens. The kit comprises a detection membrane strip, a fluorescent detection solution and reaction solutions, wherein the detection membrane strip comprises a nylon membrane and a capture probe fixed to the nylon membrane; the fluorescent detection solution comprises quantum dots for marking the capture probe and coupled with streptavidin on the surfaces; the reaction solutions include a reaction solution I, a reaction solution II, a reaction solution III and a reaction solution IV. The kit has the beneficial effects as follows: the high-throughput, high-sensitivity and high-specificity kit for the quantum dot nucleic acid detection of the urinary tract infection-causing pathogens is provided; the kit has fewer steps and obviously shorter detection time than the existing colorimetric gene chip, has lower equipment cost than an organic fluorescent gene chip, and is conducive to clinical popularization.

The invention discloses a kit and device for detecting aneuploidy of chromosomes. The device comprises a sequenced data detection module, a first coverage calculation module, a ZCNV value calculation module, a copy number variation fragment query module, a copy number variation fragment determination module, a first alpha calculation module, a second alpha calculation module, a correction module, a second coverage calculation module, a Zaneu value judgment module and a chromosome aneuploidy confirmation module, wherein the sequenced data detection module is used for obtaining sequenced data for all the chromosomes; the first coverage calculation module is used for obtaining uncorrected coverage of each chromosome; the ZCNV value calculation module is used for calculating a ZCNV value of a single sequence number of each window; the copy number variation fragment query module is used for querying fragments, of which the ZCNV value of over 80% of windows is greater than or equal to 4 or smaller than or equal to -4, with over 300Kb in the sequenced data; the copy number variation fragment determination module is used for determining copy number variation fragments of a pregnant woman to be detected; the first alpha calculation module is used for calculating a parameter alpha according to a formula (1); the second alpha calculation module is used for calculating the parameter alpha according to a formula (2); the correction module is used for correcting the uncorrected coverage so as to obtain corrected coverage; the second coverage calculation module is used for calculating a Zaneu value of each chromosome; the Zaneu value judgment module is used for judging whether the Zaneu value is not smaller than 3 or not; the chromosome aneuploidy confirmation module is used for determining that the chromosomes have aneuploidy. The detection is more accurate.

The invention discloses a primer composition for guiding nitroglycerin medication and healthy drinking, a multiple gene detection kit and a use method of the kit, and the kit comprises the primer composition, a PCR buffer solution and a positive reference substance, and the PCR buffer solution comprises ultrapure water, an X solution, a 10*PCR (polymerase chain reaction) buffer solution, a PCR primer, a 25mM magnesium chloride solution and DNA polymerase, the primer composition comprise two forward and reverse amplification primers of different gene types on the 2 SNP sites of genes related to the nitroglycerin medication and healthy drinking and forward and reverse amplification primers capable of reflecting internal reference, the gene sequences of the primers are represented as SEQ ID NO.1-NO.8; the use method comprises the step of acquiring a sample and extracting nucleic acid, the step of performing the PCR reaction by using extracted nucleic acid as a template, and the final step of separating the sample through capillary electrophoresis. The primer composition has the advantages of being strong in specificity, high in accuracy, high in flux, strong in reliability, low in cost and free from false negative result.

The invention provides an immunochromatographic test strip. The test strip comprises a sample pad, a binding pad, a cellulose nitrate membrane, an absorbent pad and a backing pad, the cellulose nitrate membrane comprises a detection line and a quality control line, and the cellulose nitrate membrane also comprises a double antibody line. The double antibody line is arranged between the detection line and the quality control line. The invention also provides a making method and a detection method of the immunochromatographic test strip. The immunochromatographic test strip reserves the advantages of simple operation, simple structure and low cost of traditional immunochromatographic test strips, effectively avoids the false negative phenomenon appearing in the detection of high concentration of a substance to be tested of traditional test strips, effectively improves the detection accuracy of immunochromatography, and enlarges the linear detection range; and the test strip comprehensively utilizes the signal intensities of the above lines in a display area and the relationship among the signal intensities of the three lines not limited to the signal intensity of the detection line, so the test strip can be used to accurately determine the concentration of the substance to be tested, and the sensitivity and the specificity of immunochromatographic detection are greatly improved.

The invention discloses a kit for synchronously detecting fifteen hemorrhagic fever pathogens and a detection method of the kit. The kit comprises DEPC (diethylpyrocarbonate) water, a 5*RT (reverse transcription) buffer, a reverse transcription primer, a reverse transcriptase, an X solution, a 10*PCR (polymerase chain reaction) buffer, a PCR primer, a 25mM magnesium chloride solution, a DNA (deoxyribonucleic acid) polymerase and a positive control, and is characterized in that the reverse transcription primer comprises RT amplification primers of the nine hemorrhagic fever pathogens and a human RNA (ribonucleic acid) internal reference, and has a gene sequence shown as SEQ ID NO. 1-10 (sequence identifier number 1-10), and the PCR primer comprises forward and reverse PCR amplification primers of the rest six hemorrhagic fever pathogens, a human DNA internal reference and a reaction internal reference, and PCR amplification primers of the nine hemorrhagic fever pathogens and the human RNA internal reference, and has a gene sequence show as SEQ ID NO. 10-36. The kit and the detection method have the advantages of high specificity, sensitivity, flux and reliability, low cost, and no false negative results.

The invention discloses a method for detecting an ER gene of peripheral blood circulating tumor cells of a patient suffering from advanced breast cancer. The method comprises the steps of conducting separation with a membrane filtration device, so that CTC in peripheral blood of the patient suffering from advanced breast cancer is obtained; identifying the peripheral blood circulating tumor cells of the patient suffering from advanced breast cancer through the cellular immunofluorescence technique; preparing thin layer sections through the cell paraffin block technique; further detecting the ER expression condition of the peripheral blood circulating tumor cells of the patient suffering from advanced breast cancer through the immunohistochemical technique. According to the method, CTCs are separated and enriched by means of the ISET technique, and the CTCs are identified through the cellular immunofluorescence technique, so that the difficulty existing in CTCs identification conducted through the pure ISET technique and false negativeness existing in CTCs identification conducted through the pure immunological detection technique are overcome. The technique is not high in equipment requirement, the method is easy to grasp, and real-time monitoring can be conducted. By means of the technical method, the ER expression condition of the patient suffering from advanced breast cancer can be detected without picking breast cancer tissues.

The invention discloses an antigen polypeptide pool for detecting Mycobacterium tuberculosis infection. The specific antigen polypeptide pool can specifically stimulate Mycobacterium-tuberculosis-infected fresh whole blood and specifically secrete IFN-gamma, thereby increasing the detection sensitivity. The invention provides a novel detection reagent applicable to detection of Mycobacterium tuberculosis infection. The experiment proves that the peripheral blood can be directly utilized to perform antigenic stimulation without the need for separating peripheral blood mononuclear cells. The experimental data shows that when being used for detecting Mycobacterium tuberculosis infection, the antigen polypeptide pool has the advantages of higher sensitivity, higher specificity and lower cost, is simple to operate, and has higher clinical application value.

The invention relates to a blaKPC (Klebsiella Pneumoniae Carbapenmase) gene detection kit, and particularly to a kit for detecting klebsiella pneumoniae KPC type carbapenemases (blaKPC) gene by utilizing a composite probe technology and a real-time fluorescence PCR (Polymerase Chain Reaction) technology. Through qualitative detection for the blaKPC gene in a sample, the kit can be widely applied to auxiliary diagnosis of bacterial infection including the blaKPC gene.

The invention relates to a kit for detecting ITD (internal tandem duplication) mutation in an FLT3 (Fms-like tyrosine kinase 3) gene juxtamembrane domain and in particular relates to a kit for detecting the FLT3-ITD in a clinical sample by using a fluorescence PCR (Polymerase Chain Reaction) capillary electrophoresis technology. The kit mainly comprises a PCR amplified reaction solution, a negative control product, a positive control product, a plurality of sealed reagent bottles or pipes which cover the kit as well as packaging boxes which are used for separating and concentratively packaging the reagent bottles or pipes, and the size and gene dosage of each amplified fragment are determined by using an electrophoresis method. The kit disclosed by the invention has high sensitivity and specificity in terms of detection and analysis of the FLT3-ITD in a whole blood or marrow sample and can be widely applied to the fields of judgment prognosis and guide treatment of leukemia and resurgence prevention of diseases.

The invention relates to a reagent kit of detecting human immunodeficiency virus type 1 by fluorescence quantitative RT-PCR (Reverse Transcription-Polymerase Chain Reaction), and in particular relates to a reagent kit of rapidly and quantitatively detecting infection of human immunodeficiency virus type 1 by one-step real-time fluorescence reverse transcription-polymerase chain reaction (RT-PCR). The reagent kit is high in sensitivity and specificity, is used for quantitatively detecting human immunodeficiency virus type 1 nucleic acid RNA (Ribonucleic Acid) in a serum or plasma sample and is suitable for auxiliary diagnosis of the infection of the human immunodeficiency virus type 1 and curative effect survey of drug therapy of a human immunodeficiency virus type 1 infected person.